, vol. 28, pp. 306–309 , 2014.
Background: Lupus nephritis is one of the most serious manifestations of systemic lupuserythematosus(SLE).Novelbiomark- ers are necessary to enhance the diag- nostic accuracy, prognostic stratification, monitoring of treatment response, and de- tection of early renal flares. Methods: Our study was conducted on 90 participants. They were divided into three groups, group I (controls) encompassed 30 ages and sex- matched healthy personnel. Group II in- cluded 30 non-nephritic SLE patients and finally group III included 30 SLE nephritic patients. Urinary monocyte chemoattrac- tant protein-1 (UMCP-1) and hepcidin were evaluated by ELISA technique, compared andcorrelatedindifferentgroups,witheach other and with other routine variables and with renal biopsy done to study group (III).
Results: Both UMCP-1 and hepcidin in group III showed significant increase com- pared to other two groups (controls and group II) (468 ± 128, 111 ± 12, 252 ± 56 pg/ml, respectively, for UMCP-1 and 40 ± 12, 11 ± 2, 20 ± 5 ng/ml, respectively, for hepcidin, P < 0.01). Also both UMCP-1 and hepcidin in group III showed significant increase in diffuse proliferative subgroup compared to focal proliferative and mesan- gioproliferative subgroups (580 ± 43, 502 ± 46, and 352.6 ± 100 pg/ml, respectively, for UMCP-1 and 47.8 ± 9.5, 41.4 ± 6, and 32.9 ± 10.8 ng/ml, respectively, for urinary hepcidin, P < 0.05). Conclusion: UMCP-1 and hepcidin could be associated with the susceptibility of lupus nephritis. J. Clin. Lab.Anal.28:306–309,2014. C 2014Wi- ley Periodicals, Inc. Key words: lupus nephritis; urinary biomarkers; monocyte chemoattractant protein-1; hepcidin
